ArticleCancer medicine2024
Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China.
Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Association between sexually transmitted infections and reproductive lifespan: analysis of the NHANES 1999-2023.BMC public health · 2026Article
- Informative High-Risk HPV Genotyping in Cervical Cancer Screening: Integrated Analysis of Cytology and p16/Ki67 Dual Staining.Cancers · 2026Article
- Clinical performance of triage strategies for HPV-positive women in cervical cancer screening in rural Yunnan China.BMC cancer · 2025Article
- Significance of Genotype-Specific High-Risk Human Papillomavirus Testing in Cervical Cancer Screening: A Hospital-Based Study.Journal of medical virology · 2025Article
- The triage role of cytological DNA methylation in women with non-16/18, specifically genotyping high-risk HPV infection.British journal of cancer · 2025Article
- Enhancing Cervical Cancer Screening: New Diagnostic Methodologies, Triage, and Risk Stratification in Prevention and Treatment.Life (Basel, Switzerland) · 2025Review
- Development, validation, and clinical application of a machine learning model for risk stratification and management of cervical cancer screening based on full-genotyping hrHPV test (SMART-HPV): a modelling study.The Lancet regional health. Western Pacific · 2025Article
- Integrated HPV Testing, TCT, and Colposcopic VIA/VILI Improves Detection Rate for HSIL and Cervical Cancer: A Retrospective Cohort in China.International journal of women's health · 2025Article
- Cohort analysis of high-risk HPV infection in adult women in Dapeng New District, Shenzhen, Guangdong Province, China.Frontiers in microbiology · 2025Article
- Article
- Comparative Performance of Visual Inspection with Acetic Acid and Colposcopy for Detection of Cervical Precancer in Women with High-Risk Human Papillomavirus Infection: A Cross-Sectional Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
objectiveTo assess the clinical values of extended human papillomavirus (HPV) genotyping in triage of high-risk HPV-positive women, focusing on the trade-off between cervical precancer detections and colposcopy referrals.
methodsA bivariate random-effects model was used to estimate the diagnostic accuracy of primary HPV screening with following triage strategies to detect cervical precancers: (i) partial genotyping for HPV16/18 combined with cytological testing at atypical squamous cells of undetermined significance threshold (used as the comparator), (ii) genotyping for HPV16/18/58/52, (iii) genotyping for HPV16/18/58/52/33, (iv) genotyping for HPV16/18/58/33/31, (v) genotyping for HPV16/18/58/52/33/31, and (vi) genotyping for HPV16/18/58/52/33/31/39/51. Internal risk benchmarks for clinical management were used to evaluate the risk stratification of each triage strategy.
resultsA total of 16,982 women (mean age 46.1 years, range 17-69) were included in this analysis. For CIN3+ detection, triage with HPV16/18/58/33/31 genotyping achieved lower positivity (6.85% vs. 7.35%, p = 0.001), while maintaining similar sensitivity (91.35% vs. 96.42%, p = 0.32) and specificity (94.09% vs. 93.67%, p = 0.56) compared with the comparator strategy. Similar patterns were observed for CIN2+ detection. Women with a positive HPV16/18/58/33/31 genotyping test had high enough risk for CIN3+ for colposcopy referral, while the risk for women with a negative test was below the 1-year return decision threshold according to internal benchmarks.
conclusionsOur findings suggested extended HPV genotyping is of potential to be used as a triage technique integrated into HPV-based cervical cancer screening, leading to reduced need for colposcopy referral while maintaining similar disease detection and efficient risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.